Brian McNamee Elected to Gen-Probe Board of Directors

SAN DIEGO, March 22 /PRNewswire-FirstCall/ -- Gen-Probe Incorporated (Nasdaq: GPRO) announced today that Brian McNamee, MBBS, CEO and managing director of the leading international biopharmaceutical company CSL Ltd., has been elected to its board of directors. Gen-Probe's board now has nine members, including seven independent directors.

"We are delighted that Brian has agreed to re-join Gen-Probe's already strong board," said Hank Nordhoff, the Company's chairman. "We are sure to benefit from his experiences leading a multi-billion-dollar company, and from his broad industry knowledge and international perspective."

Dr. McNamee, 53, served on Gen-Probe's board from the time of the Company's September, 2002 spin-off from Chugai until May, 2007. He has served as CEO and managing director of CSL since 1990. CSL has a combined heritage of outstanding contributions to medicine and human health, with more than 90 years experience in the development and manufacture of vaccines and plasma protein biotherapies. Dr. McNamee obtained his medical degree from the University of Melbourne.

About Gen-Probe

Gen-Probe Incorporated is a global leader in the development, manufacture and marketing of rapid, accurate and cost-effective molecular diagnostic products and services that are used primarily to diagnose human diseases, screen donated human blood, and ensure transplant compatibility. Gen-Probe has approximately 27 years of NAT expertise, and received the 2004 National Medal of Technology, America's highest honor for technological innovation, for developing NAT assays for blood screening. Gen-Probe is headquartered in San Diego and employs approximately 1,300 people. For more information, go to www.gen-probe.com.

Caution Regarding Forward-Looking Statements

Any statements in this press release about our expectations, beliefs, plans, objectives, assumptions, future events or performance are not historical facts and are forward-looking statements. These statements are often, but not always, made through the use of words or phrases such as believe, will, expect, anticipate, estimate, intend, plan and would. Forward-looking statements are not guarantees of performance. They involve known and unknown risks, uncertainties and assumptions that may cause actual results to differ materially from those expressed or implied. Some of the risks, uncertainties and assumptions that could cause actual results to differ materially from estimates or projections in the forward-looking statement include, but are not limited to, the risk that Gen-Probe may not be able to retain its key employees and directors. For additional information about risks and uncertainties we face and a discussion of our financial statements and footnotes, see documents we have filed with the SEC, including our Report on Form 10-K for the fiscal year ended December 31, 2009, and all our periodic filings made with the SEC. We assume no obligation and expressly disclaim any duty to update any forward-looking statement to reflect events or circumstances after the date of this press release or to reflect the occurrence of subsequent events.